These agents fall into several classes that include statins, fibric acid derivatives, bileacid sequestrants, nicotinic acid (also known as niacin) and the cholesterol absorption inhibitors.
They also ignore decades of prior clinical end point data, such as NIH CPPT and POSCH on bileacid sequestration, that formed the basis for NCEP ATP I prior to any statin clinical outcomes.
In LRC-CPPT, patients on cholestyramine, a bileacid sequestrant resin, had 20% lower LDL as compared to an 8% drop on placebo and, after seven years, had a 24% reduction in CV deaths versus placebo.